Skip to content
10-Q

Quarterly Report

BENITEC BIOPHARMA INC. BNTC

0001193125-25-119383

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · May 14, 2025 25.6M sh
Cash And Equivalents Q3 2025 · Mar 31, 2025 $103.58M
Cash And Equivalents Q3 2025 · Jun 30, 2024 $50.87M
Current Liabilities Q3 2025 · Mar 31, 2025 $7.03M
Current Liabilities Q3 2025 · Jun 30, 2024 $4.92M
Total Liabilities Q3 2025 · Mar 31, 2025 $7.64M
Total Liabilities Q3 2025 · Jun 30, 2024 $4.96M
Current Assets Q3 2025 · Mar 31, 2025 $104.01M
Current Assets Q3 2025 · Jun 30, 2024 $51.67M
Total Assets Q3 2025 · Mar 31, 2025 $105.21M
Total Assets Q3 2025 · Jun 30, 2024 $52.21M
Shares Diluted restated Q3 2025 · Mar 31, 2024 18.28M sh
Shares Diluted restated Q3 2025 · Mar 31, 2024 15.88M sh
Capex Q3 2025 · Mar 31, 2024 $179K
Operating Cash Flow Q3 2025 · Mar 31, 2024 −$16.11M
Stockholders Equity Q3 2025 · Mar 31, 2024 $11.5M
Stockholders Equity Q3 2025 · Dec 31, 2023 $15.47M
Stockholders Equity Q3 2025 · Sep 30, 2023 $22.31M
Stockholders Equity Q3 2025 · Jun 30, 2023 $202K
Eps Diluted restated Q3 2025 · Mar 31, 2024 −$0.23
Eps Diluted restated Q3 2025 · Mar 31, 2024 −$1.11
Eps Basic restated Q3 2025 · Mar 31, 2024 −$0.23
Eps Basic restated Q3 2025 · Mar 31, 2024 −$1.11
Sga Expense Q3 2025 · Mar 31, 2024 $1.58M
Sga Expense Q3 2025 · Mar 31, 2024 $4.95M
Rd Expense Q3 2025 · Mar 31, 2024 $2.57M
Rd Expense Q3 2025 · Mar 31, 2024 $12.1M
Net Income Q3 2025 · Mar 31, 2024 −$4.28M
Net Income Q3 2025 · Mar 31, 2024 −$17.03M
Net Income Q3 2025 · Dec 31, 2023 −$6.8M
Net Income Q3 2025 · Sep 30, 2023 −$5.95M
Operating Income Q3 2025 · Mar 31, 2024 −$4.14M
Operating Income Q3 2025 · Mar 31, 2024 −$16.94M
Revenue Q3 2025 · Mar 31, 2024 $0
Revenue Q3 2025 · Mar 31, 2024 $0